Skip to main content
Category

News Archive

2017 BioHealth Capital Region Forum

By News Archive

Join us as we showcase accomplishments and discuss opportunities for the future of the BioHealth industry in the BioHealth Capital Region.

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Paragon Bioservices, INOVA, University System of Maryland and MedImmune/AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum — a catalyst for public-private, academia-industry, and seasoned-rising stars to join forces for the good of the region. We are excited to bring you an exceptional line up of speakers. The program will feature sessions that focus on Advancing Science and Accelerating Innovation.

April 19 – 20, 2017

One MedImmune Way, Gaithersburg, MD 20878

Register at www.bhcrforum.com

For more information, contact Amy Rubenstein at 513-238-8606 or amy@taylormadeexperience.com.

red-flag-pixa

Startup Professionals Musings: 13 Red Flags To Avoid In Your Investor Funding Pitch

By News Archive

red-flag-pixa

After listening to hundreds of startup pitches, and reading even more business plans, most new venture investors develop their own favorite list of “red flags” that signal the beginning of the end of their interest. Others, like Guy Kawasaki, have irreverently called some of these “entrepreneur lies,” but I prefer to think of them as innocent enhancements or omissions that can kill your deal.

At any rate, here is my own list of red flags, from my years of experience advising and investing in aspiring entrepreneurs, which cause me to lose interest and start looking for a way out the door:

Read More
cambridge-university-press-logo

Organization for rare diseases India (ORDI) – addressing the challenges and opportunities for the Indian rare diseases’ community | Genetics Research | Cambridge Core

By News Archive

cambridge-university-press-logo

In order to address the unmet needs and create opportunities that benefit patients with rare disease in India, a group of volunteers created a not-for-profit organization named Organization for Rare Diseases India (ORDI; www.ordindia.org). ORDI plans to represent the collective voice and advocate the needs of patients with rare diseases and other stakeholders in India. The ORDI team members come from diverse backgrounds such as genetics, molecular diagnostics, drug development, bioinformatics, communications, information technology, patient advocacy and public service. ORDI builds on the lessons learned from numerous similar organizations in the USA, European Union and disease-specific rare disease foundations in India. In this review, we provide a background on the landscape of rare diseases and the organizations that are active in this area globally and in India. We discuss the unique challenges in tackling rare diseases in India, and highlight the unmet needs of the key stakeholders of rare diseases. Finally, we define the vision, mission, goals and objectives of ORDI, identify the key developments in the health care context in India and welcome community feedback and comments on our approach.

Read More
tesla-logo

Elon Musk: Humans Need to Merge With Machines to Remain Relevant – Fortune.com

By News Archive

tesla-logo

Tesla and SpaceX founder Elon Musk has a suggestion for humans who want to stay relevant in a future of artificial intelligence: merge with the machines.

“Over time I think we will probably see a closer merger of biological intelligence and digital intelligence,” Musk said at the World Government Summit in Dubai, according to CNBC. “It’s mostly about bandwidth, the speed of the connection between your brain and the digital version of yourself, particularly output.”

Read More
orgenesis-logo

Orgenesis Approved for Euro 12.3 Million European Grant for Further Development of Its Type 1 Diabetes Program

By News Archive

orgenesis-logo

Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its Belgian subsidiary, Orgenesis SPRL, has received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DGO6) for a budget of EUR 12.3 million ($12.8 million) support program for the GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium. The project support will be for a period of three years commencing on January 1, 2017.

Of the approved amount, a total of EUR 3.3 million is budgeted for a development work at our Belgian-based subsidiary, MaSTherCell S.A.

Read More
mri-brain-pixa

This Technology Could Finally Make Brain Implants Practical

By News Archive

mri-brain-pixa

In labs testing how brain implants could help people with physical disabilities, tales of success can be bittersweet.

Experiments like those that let a paralyzed person swig coffee using a robotic arm, or that let blind people “see” spots of light, have proven the huge potential of computers that interface with the brain. But the implanted electrodes used in such trials eventually become useless, as scar tissue forms that degrades their electrical connection to brain cells (see “The Thought Experiment”).

Read More
brian-darmody-2-umd-image

Maryland: The state of research – Maryland Daily Record

By News Archive

brian-darmody-2-umd-image

Which state has the nation’s most research-intensive economy? California? Massachusetts? North Carolina?

Actually it’s Maryland. A greater portion of Maryland’s economy comes from private, federal, and university research spending than any state (with the exception of rural New Mexico with its two large federal labs).  But not enough of us recognize that.

Read More
nhlbi-nih-logo

NHLBI Funding & Research Opportunities and Announcements for February 10, 2017

By News Archive

nhlbi-nih-logo

Funding and Research Opportunities

The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:

Notices:

  • Impact of Washington, DC Area Federal Office Operating Status on NIH Grant Application Due Dates 
  • Notice of NIA’s Participation in PA-17-101 “Research on the Health of Women of Underrepresented, Understudied and Underreported (U3) Populations – An ORWH FY17 Administrative Supplement (Admin Supp)”
  • NHLBI Priorities for HIV Research and Funding 
  • Notice of NLM’s Participation in PA-17-101 “Research on the Health of Women of Underrepresented, Understudied and Underreported (U3) Populations An ORWH FY17 Administrative Supplement (Admin Supp)”

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.